CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BioNTech SE - ADR is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BioNTech SE - ADR
AN DER GOLDGRUBE 12
Phone: +49 49613190840p:+49 49613190840 MAINZ, 55131  Germany Ticker: 0A3M0A3M
Business Summary
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
8732 Commercial economic, sociological, and educational research
8733 Noncommercial research organizations
2836 Biological products, except diagnostic substances
2835 In vitro and in vivo diagnostic substances
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Supervisory Board HelmutJeggle 54 1/1/2021 1/1/2008
Chief Executive Officer, Member of the Management Board UgurSahin 58
Independent Deputy Chairman of the Supervisory Board UlrichWandschneider 62 1/1/2022 1/1/2018
11 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Instadeep Ltd 5 Merchant Square London United Kingdom
Neon Therapeutics Inc 40 Erie Street Cambridge MA United States

Business Names
Business Name
0A3M
BioNTech (Shanghai) Pharmaceuticals Co., Ltd
BioNTech Australia Pty Ltd
39 additional Business Names available in full report.

General Information
Number of Employees: 6,133 (As of 12/31/2023)
Outstanding Shares: 239,739,752 (As of 9/30/2024)
Shareholders: 2
Stock Exchange: NASD
Fax Number: +49 61319084390
Email Address: info@biontech.de


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024